首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Construction of a composite sponge containing tilapia peptides and chitosan with improved hemostatic performance
【24h】

Construction of a composite sponge containing tilapia peptides and chitosan with improved hemostatic performance

机译:含有罗非鱼肽和壳聚糖的复合海绵的构建,具有改善的止血性能

获取原文
获取原文并翻译 | 示例
           

摘要

Despite superior hemostasis and repair function, tilapia peptide's application as wounding dressing is greatly limited due to its poor biostability. To expand its application in wounding dressing area, chitosan (CS), with antibacterial activity, biocompatibility and biodegradability, was used to encapsulate tilapia peptides using ionic crosslink method. The results show 10.6w% (loading capacity) of the tilapia peptides are homogenously dispersed in surface or interior of the as-fabricated chitosan/tilapia peptides microspheres (CS/TPM), which leads to greatly improved biostability. In addition, a new composite sponge using CS/TPM as fillers and CS as matrix was then constructed (S-CS/TPM) and used for hemorrhage control. The results indicate that S-CS/TPM can absorb large volume of water, accelerate blood clotting, increase platelet adhesion and promote conversion of fibrinogen to fibrin. Compared with the CS andCS/TPM, the hemostatic efficiency of S-CS/TPM in New Zealand rabbit ear and femoral artery models is much higher. Particularly, the bleeding time was shortened greatly, and the bleeding volume was reduced significantly. In conclusions, our results suggested that S-CS/TPM is a promising hemostatic adjuvant. (C) 2019 Elsevier B.V. All rights reserved.
机译:尽管止血和修复功能卓越,但罗非鱼肽作为伤口敷料的应用是由于其可生物萎缩差而受到极大的限制。为了扩展其在伤口敷料区域的应用,使用抗菌活性,生物相容性和生物降解性的壳聚糖(CS),用于使用离子交联方法包封罗非鱼肽。结果显示罗非鱼肽的10.6W%(装载能力)在制造的壳聚糖/罗非鱼肽微球(Cs / TPM)的表面或内部均匀分散,这导致恶性稳定性大大提高。此外,然后构建使用Cs / TPM作为填料和Cs作为基质的新复合海绵,并用于出血控制。结果表明,S-CS / TPM可以吸收大量的水,加速血液凝固,增加血小板粘附,促进纤维蛋白原转化为纤维蛋白。与CS和CS / TPM相比,新西兰兔耳和股动脉模型S-CS / TPM的止血效率要高得多。特别是,出血时间大大缩短,并且出血量显着降低。在结论中,我们的结果表明S-CS / TPM是一个有前途的止血佐剂。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号